Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 5, 2008, Pages 949-958

  Turkoz, Ibrahim ^a   Bossie, Cynthia A ^a   Dirks, Bryan ^a   Canuso, Carla M ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antipsychotic; Paliperidone ER; Path analysis; Psychotropic; Schizophrenia

Indexed keywords

PALIPERIDONE; PLACEBO;

ANXIETY DISORDER; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; GAIT; HUMAN; HYPERKINESIA; INSOMNIA; MORNING DOSAGE; MOTOR DYSFUNCTION; MULTICENTER STUDY; MUSCLE RIGIDITY; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PARALLEL DESIGN; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; SALIVATION; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; TABLET; TREMOR;

EID: 56849096505     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Andreasen NC. 1982, Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry, 39:784-8.
2. Ayuso-Gutierrez JL, del Rio Vega JM. 1997. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res, 28:199-206.
3. Barnes TR. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry, 154:672-6.
4. Carpenter WT Jr, Heinrichs DW, et al. 1985. Treatment of negative symptoms. Schizophr Bull, 11:440-52.
5. Davidson L, McGlashan TH. 1997. The varied outcomes of schizophrenia. Can J Psychiatry, 42:34-43.
6. Davidson M, Emsley R, Kramer M, et al. 2007. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res, 93:117-30.
7. Docherty JP, Grogg AL, Kozman C, et al. 2002. Antipsychotic maintenance in schizophrenia: partial compliance and clinical outcome. American College of Neuropsychopharmacology 41st Annual Meeting; San Juan, Puerto Rico. December 8-12.
8. Gharabawi G, Bossie C, Turkoz I, et al. 2007. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. J Nerv Mental Dis, 195:976-82.
9. Guy WA. 1972. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education and Welfare. p. 533-7.
10. Guy WA. 1976. Clinical global impressions. In: ECDEU assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education and Welfare. p. 218-222.
11. Kane J, Canas F, Kramer M, et al. 2007. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res, 90:147-61.
12. Kay SR, Fiszbein A, Opler LA. 1987. The Positive And Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull, 13:261-76.
13. King DJ. 1998. Drug treatment of the negative symptoms of schizophrenia. Eur Neuropsychopharmacol, 8:33-42.
14. Kirkpatrick B, Fenton WS, Carpenter WT Jr, et al. 2006. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull, 32:214-9.
15. Leucht S, Pitschel-Walz G, Abraham D, et al. 1999. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res, 3 5:51-68.
16. Marder SR, Davis JM, Chouinard G. 1997. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry, 58:538-46.
17. Marder SR, Kramer M, Ford L, et al. 2007. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry, 62:1363-70.
18. Milev P, Ho BC, Arndt S, et al. 2005. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry, 162:495-506.
19. Moller HJ. 1993. Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties. Eur Neuropsychopharmacol, 3:1-11.
20. Moller HJ, Muller H, Borison RL, et al. 1995. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci, 245:45-9.
21. Morosini PL, Magliano L, Brambilla L, Ugolini S, et al. 2000. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand, 101:323-9.
22. Pedhazur EJ. 1982. Path analysis. Multiple regression in behavioral research. New York: Holt.
23. Prosser ES, Csernansky JG, Kaplan J, et al. 1987. Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics. J Nerv Mental Dis, 175:100-5.
24. Simpson GM, Angus JW. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl, 212:11-9.
25. Tandon R. 2004. Quetiapine has a direct effect on the negative symptoms of schizophrenia. Hum Psychopharmacol, 19:559-63.
26. Tollefson GD, Sanger TM. 1997. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry, 154:466-74.
27. Valenstein M, Copeland LA, Blow FC, et al. 2002. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care, 40:630-9.
28. Weiden PJ, Kozma C, Grogg A, et al. 2004. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv, 55:886-91.